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Background: Surgery is not generally recommended for non-small cell lung cancer
(NSCLC) patients with malignant pleural dissemination (PD). However, in some cases,
PD is found unexpectedly during surgery. There is no consensus on whether surgical
intervention can provide survival benefit for them. We investigated the role of surgery in
NSCLC patients with unexpected PD by a cohort study.
Methods: Clinical data of consecutive patients who intended to undergo radical
surgery for NSCLC between January 2010 and December 2015 at Shanghai Chest
Hospital and Huadong Hospital were collected from a lung cancer database. Patients
diagnosed with unexpected malignant pleural nodules intraoperatively were enrolled in
this retrospective study.
Results: A total of 181 NSCLC patients were diagnosed with unexpected malignant
PD intraoperatively and confirmed with postoperatively histological examinations. Out
of these, 80 (44.2%) patients received pleural nodule biopsies alone, and 101 (55.8%)
received primary tumor resection (47 with sublobar resection and 54 with lobectomy).
The median progression-free survival and overall survival for all patients were 13
and 41 months respectively. Patients in the resection group had significantly better
progression-free survival (19.0 vs. 10.0 months, P < 0.0001) and overall survival
(48.0 vs. 33.0 months, P < 0.0001) than patients in the biopsy group. In the resection
group, there was no statistical difference between patients with sublobar resection
and lobectomy (P = 0.34). Univariate and multivariate analyses identified primary
tumor resection, targeted adjuvant therapy, and tumor size (≤ 3 cm) as independent
prognostic factors.
Conclusions: NSCLC patients with unexpected intraoperative PD potentially benefited
from surgical resection of the primary tumor and multidisciplinary targeted therapy,
particularly when tumor size did not exceed 3 cm. Our data demonstrated that the
resection type was not associated with survival differences, which remains to be defined
with a larger sample size.
Keywords: non-small cell lung cancer, malignant pleural nodule, surgery, epidermal growth factor receptor,
survival
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INTRODUCTION
About 4.5–7.5% of patients with non-small cell lung cancer
(NSCLC) are confirmed with pleural dissemination (PD) at
diagnosis (1, 2). NSCLC with PD is typically staged as M1a in
the 7th and 8th tumor, node, and metastasis (TNM) classification
because NSCLC patients with PD had a generally poor prognosis
(3–5). The median overall survival (OS) and 5-year survival rate
were 8 months and <2%, respectively (2).
Because NSCLC with PD are classified as M1a stage,
thus, systemic chemotherapy or targeted therapy, rather than
surgical resection, is recommended as standard care for
patients at initial diagnosis (6). However, sometimes PD
is found unexpectedly during operation. In this case, it is
difficult for surgeons to determine whether to proceed the
resection of the primary tumors or not, given that, on
one hand, there is a lack of evidence of surgical role in
unexpected PD cases due to the low incidence of unexpected
PD cases, and, on the other hand, there is no technical
difficulty with surgical excision of primary and metastatic
pleural lesions. Furthermore, with the rapid development of
targeted drugs, multidisciplinary treatment including surgery
may improve the survival of PD patients bearing a sensitive
mutation. But relevant studies focusing on targeted therapy
are limited.
In recent years, it was reported that surgical resection showed
prognosis benefits for NSCLC with malignant PD (1, 7–13).
Several studies focused on patients with PD showed good
survival after tumor resection, but without statistical difference
or control group (1, 14–17). Besides, some studies included
patients with pleural effusion >100ml in the cohort, which
could be found preoperatively and was a sign for metastasis,
leading to a potential bias for survival analysis. (7, 16, 18,
19). Li et al. (12) and Ren et al. (7) reported that surgical
resection was the significant prognostic factor of patients with
unexpected PD, but the sample size was small (43–83 cases),
which reduced the level of evidence. On the contrary, a study by
Sawabata indicated that tumor resection was not beneficial for
the survival (19). Still, the role of surgery in NSCLC with PD
remains controversial.
Given the limited evidence concerning the role of surgical
resection in NSCLC patients with unexpected PD detected
during surgery, we conducted a retrospective study with
larger sample size to analyze the clinical characteristics,
pathological features, positive mutations and prognosis
of patients who intended to undergo surgery and were
unexpectedly found to have intraoperative malignant pleural
nodules (MPN).
Abbreviations: ALK, anaplastic lymphoma kinase; CI, confidence interval;
CT, computed tomography; EGFR, epidermal growth factor receptor; HR,
hazard ratio; MPN, malignant pleural nodules; MRI, magnetic resonance
imaging; NSCLC, non-small cell lung cancer; OS, median overall survival; PD,
pleural dissemination; PET, positron emission tomography; PFS, progression-free




Clinical data of 21,591 consecutive patients who intended to
undergo radical surgery for NSCLC between January 2010
and December 2015 at Shanghai Chest Hospital and Huadong
Hospital were collected. The patients with unexpected PD,
Eastern Cooperative Oncology Group performance status (PS) of
0 to 1 were enrolled in this study. Unexpected PD is defined as (1)
preoperative assessments did not detect PD or distant metastasis;
(2) no malignant pleural effusion was found preoperatively;
(3) PD was only accidentally identified during operations; (4)
postoperative pathology confirmed the tumor dissemination to
pleural. PD could be separated into localized MPN (several local
nodules which could be resected by limited resection) or diffused
MPN (uncountable nodules distributed over the parietal pleura).
Clinical characteristics of the patients and respective tumors
were abstracted from the electronic medical records by
professional staff. NSCLC staging was performed according to
the 8th TNM classification (5). Given that the pathological
information is incomplete in a considerable number of patients,
for example, patients receiving biopsy only or undergoing
resection but without systemic lymph node dissection, thus the
concept of the best stage instead of the pathological stage was
used, which was based on the pathological stage if available,
otherwise, the clinical stage would be used instead. Meanwhile,
considering the inaccuracy of the stage information, it was
excluded in the analysis of prognostic factors. This study was
approved by the committees for ethical review of research at
Shanghai Chest Hospital and Huadong Hospital, and informed
consent was not required because of the retrospective nature of it.
Clinical Assessments
All patients underwent thorough preoperative evaluations
preoperatively, including physical examination, routine
laboratory tests, serum tumor markers (carcinoembryonic
antigen, cancer antigen 125, neuron-specific enolase, cyfra21-1,
squamous cell carcinoma antigen), chest computed tomography
(CT), respiratory function test, echocardiography, and
electrocardiogram. Distant or extrathoracic metastasis was
excluded by brain magnetic resonance imaging (MRI),
abdominal CT or sonography, and bone scanning. Positron
emission tomography (PET) was applied if applicable.
Operations
Posterolateral thoracotomy or video-assisted thoracoscopic
surgery (VATS) was performed by surgeons according to the
patient’s conditions. When pleural nodule was found during
the initial exploration, a frozen section biopsy of the pleural
was taken to confirm the pleural metastasis. Then different
types of surgical resections were chosen by surgeons based
on their experience, beliefs, and conditions of patients. These
included pleural nodules biopsy, primary tumor resection
(wedge resection, segmentectomy, or lobectomy) with or without
systemic lymphadenectomy, lymph node sampling, pleurectomy,
or pleural nodule resection or electrocautery.
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Follow-Up
All patients were instructed to receive 4–6 cycles of adjuvant
platinum-based chemotherapies or first-line targeted therapies
if they harbored sensitive mutations for medications.
Radiotherapies were performed for local progression or distant
metastasis, according to the radiation oncologists. Adjuvant
therapies were prescribed within 1 month postoperatively.
The follow-up visit was scheduled as the National
Comprehensive Cancer Network (NCCN) guidelines (6).
All patients were evaluated by a chest CT scan and abdominal
sonography. Additionally, brainMRI and bone scintigraphy were
regularly performed according to the physicians when necessary.
When patients suffered disease progression, subsequent
chemotherapy, or targeted therapy was recommended based on
the suggestions by oncologists.
OS and progression-free survival (PFS) were regarded as the
primary endpoints of the study. OS was recorded from the date
of surgery to the date of death or the last follow-up visit. PFS
was measured from the date of surgery until the date of the first
documented progression or the last follow-up. The closing date
of the follow-up for this study was January 31, 2018. Information
was obtained from patients through phone calls and outpatient
re-visit records.
Statistical Analysis
Measurement data were assessed to compare different patient
groups by the chi-square test and Fisher exact probability
test for categorical variables and two-tailed Student’s t-test
for continuous variables. And continuous variables were
summarized as median and range. Categorical variables were
expressed by the median and percentage. Survival curves were
obtained using Kaplan-Meier method and compared using the
log-rank test. Univariate and multivariate analysis use the Cox
proportional hazards regression with the test level α = 0.05.
The proportional hazard assumption was examined and met
by plotting the survival curve with Kaplan-Meier method.
Significant variables in univariate analysis (defined as P < 0.15)
would be included in multivariate analysis. Other clinically
relevant factors like sex, age, and smoking history were also
included in the Cox proportional-hazards model (20). A P-value
of < 0.05 was considered statistically significant. All analyses
were conducted using SPSS 22.0 software (IBM Corporation,




Two hundred seventeen (1.0%) of 21,591 cases were found to
have a PD. After the exclusion of 36 patients not meeting the
inclusion criteria, a total of 181 patients (98/54.1%men, 83/45.9%
women) diagnosed with unexpected malignant PD through
intraoperatively or postoperatively histological examinations
were enrolled in the present study. The median age of them
was 59 years ranging 30–75 years. The characteristics of patients
and tumors were summarized in Table 1. The median follow-
up duration was 36 months (range, 4–90 months). Thirteen
(7.2%) patients were lost to follow-up. Therefore, 168 patients
were included in the survival analysis. Thirty-nine of 181
(21.5%) patients received PET, and no evidence for PD was
found preoperatively.
Surgery
Of the 181 patients, 100 (55.2%) patients underwent VATS
procedure, and 81 (44.8%) had thoracotomy. Eighty (44.2%)
received pleural nodule biopsy alone (biopsy group), and
101 (55.8%) underwent additional primary tumor resection
(resection group). In the resection group, 47 (46.5%) cases
received sublobar resection (segmentectomy in 7 cases and
wedge resection in 40 cases), and 54 (53.5%) cases had
lobectomy. Systemic lymphadenectomy and lymph node
sampling were performed in 45 and 26 cases, respectively.
Additionally, 43 (23.8%) patients were detected with localized
MPN intraoperatively, while 138 (76.2%) had diffused
MPN (Table 2). No severe intraoperative and postoperative
complications occurred. There was no postoperative mortality in
neither group.
Pathology
Pathologic types of these patients included adenocarcinoma (155;
85.6%), squamous cell carcinoma (13; 7.2%), adenosquamous cell
carcinoma (5; 2.8%), large cell carcinoma (3; 1.6%), and others (5;
2.8%). Adenocarcinoma was the predominant pathological type
in both the biopsy and resection groups. The patients with the T2
or N2 stage were in the majority, accounting for 44.2 and 36.5%,
respectively (Table 2). Additionally, sensitive mutations were
examined for targeted therapies after surgery, and positive results
were found which included epidermal growth factor receptor
(EGFR) mutations in 65 of 115 (56.5%) cases (38 with a deletion
in exon 19, 27 with a point mutation at codon 858 in exon 21,
and 1 with an insertion mutation in exon 20), and anaplastic
lymphoma kinase (ALK) rearrangement in 12 of 63 (19.0%) cases.
Adjuvant Therapies
One hundred and thirty nine (82.7%) patients undertook
platinum-based chemotherapies as first-line treatment, of which
three patients received sequential EGFR-TKIs. Twenty-seven
patients undertook targeted therapy as first-line treatment with
EGFR-TKIs, including gefitinib (Iressa), erlotinib (Tarceva),
and icotinib (Conmana) and anaplastic lymphoma kinase
tyrosine kinase inhibitor (ALK-TKI) (crizotinib, Xalkori). After
disease recurrence was detected, second-line chemotherapies or
targeted therapies were prescribed. In total, 99 of 160 (61.9%)
patients received TKIs postoperatively (Table 1). Particularly,
those EGFR-mutant patients harboring EGFR substitution of
threonine 790 with methionine (T790M) received osimertinib
(AZD9291) after drug resistance of former EGFR-TKIs in 15
cases. Radiotherapy was administered in 56 patients for local
control or metastasis.
Survival
The median PFS and median OS were 13 months and 41 months,
respectively. The 3- and 5-year PFS and survival rate for all
patients were 13.1%, 5.7%, and 56.0%, 28.7%, respectively.
Frontiers in Surgery | www.frontiersin.org 3 June 2021 | Volume 8 | Article 679565
Fan et al. Lung Cancer Unexpected Pleural Dissemination
TABLE 1 | Baseline clinical features of pleural biopsy group and primary tumor resection group.
Variables Total (n = 181) Biopsy group (n = 80) Resection group (n = 101) P-value
(count, %) (count, %) (count, %)
Age (years, median, range) 59, 30–75 60, 35–75 57.5, 30–75 0.39
Gender 0.34
Male 98 (54.1) 40 (50) 58 (57.4)
Female 83 (45.9) 40 (50) 43 (42.6)
Location 0.77
Right 110 (60.8) 48 (60.0) 62 (61.4)
Left 71 (39.2) 32 (40.0) 39 (38.6)
Smoking history 0.89
Yes 62 (34.3) 27 (33.8) 35 (34.7)
No 119 (65.7) 53 (66.2) 66 (65.3)
Performance status 0.31
0 141 (77.9) 59 (73.8) 82 (81.2)
1 40 (22.1) 21 (26.2) 19 (18.8)
Tumor location types 0.189
Central 29 (16.0) 16 (20.0) 13 (12.9)
Peripheral 152 (84.0) 64 (80.0) 88 (87.1)
Chemotherapy 0.58
Yes 163 (90.1) 73 (91.2) 90 (89.1)
No 18 (9.9) 7 (8.8) 11 (10.9)
Targeted therapy 0.11
Yes 99 (54.7) 38 (47.5) 61 (60.4)
No 61 (33.7) 29 (36.3) 32 (31.7)
Unknown 21 (11.6) 13 (16.2) 8 (7.9)
EGFR mutation 0.35
Yes 65 (35.9) 21 (26.2) 44 (43.6)
No 50 (27.6) 20 (25.0) 30 (29.7)
Unknown 66 (36.5) 39 (48.8) 27 (26.7)
Radiotherapy 0.15
Yes 56 (30.9) 22 (27.5) 34 (33.7)
No 88 (48.6) 36 (45.0) 52 (51.5)
Unknown 37 (20.4) 22 (27.5) 15 (14.8)
EGFR, epidermal growth factor receptor.
Clinicopathological Characteristics and Survival
Comparison of Patients in the Biopsy and Resection
Group
There is no significant difference concerning the baseline
characteristics of patients (Table 1). However, the resection
group has significantly smaller tumor size (median 3.0 vs.
3.75 cm; P = 0.004) and less cases with diffused MPN (67/66.3%
vs. 71/88.8%; P < 0.001) than those in the biopsy group.
Additionally, in the resection group, the operation duration
(median 91.5 vs. 61min; P < 0.001) and postoperative hospital
stay (median 6 vs. 4.5 days; P = 0.008) were significantly longer,
and there were more cases of bleeding during the operation
(37/36.6% vs. 12/15.0%; P = 0.002) (Tables 1, 2).
In comparison, patients in the resection group had significant
better PFS [19.0 (95% CI: 14.7–23.3) vs. 10.0 (95% CI: 8.0–12.0)
months; P < 0.0001] and OS [48.0 (95% CI: 41.5–54.5) vs. 33.0
(95% CI: 25.0–41.0) months; P < 0.0001] than those in the
biopsy group (Figures 1A,B). The 3- and 5-year PFS rate of the
resection group were higher than the biopsy group (20.8% and
10.8% vs. 3.2% and 0%, respectively). Similar results were seen
for OS (67.8% and 37.7% vs. 41.0% and 18.2%, respectively).
Additionally, subgroup analysis showed that surgical resection
still benefited survival significantly (47.0 vs. 19.0 months, P <
0.0001) in patients who did not receive targeted therapies.
The Role of Surgical Resection, Status of MPN, and
Adjuvant Therapies
In the resection group, the 5-year survival rate and OS of
patients who underwent sublobar resection were 45.6% and
51.0 months (95% CI 33.6–68.4), respectively, while those of
patients underwent lobectomy were 29.1% and 48.0 months
(95% CI 39.9–56.1). There was no statistical difference in these
different types of surgical resection (P = 0.34), although the
survival of patients with sublobar resection tended to be better.
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TABLE 2 | Operative and pathological findings of pleural biopsy group and primary tumor resection group.
Variables Total (n = 181) Biopsy group (n = 80) Resection group (n = 101) P-value
(count, %) (count, %) (count, %)
Surgery method <0.001*
Biopsy alone 80 (100.0) 0 (0)
Sublobar resection 0 (0) 47 (46.5)
Wedge resection 0 (0) 40
Segmentectomy 0 (0) 7
Lobectomy 0 (0) 54 (53.5)
Surgical approach 0.06
VATS 100 (55.2) 51 (63.8) 49 (48.5)
Thoracotomy 81 (44.8) 29 (36.2) 52 (51.5)
Lymph node resection <0.001*
No 110 (60.8) 69 (86.3) 41 (40.6)
Lymph node sampling 26 (14.4) 11 (13.7) 15 (14.8)
Lymphadenectomy 45 (24.8) 0 (0) 45 (44.6)
Operation duration (minutes, median, range) 75, 15–230 61, 25–149 91.5, 15–230 <0.001*
Operative bleeding (ml) 0.002*
≤100 132 (72.9) 68 (85.0) 64 (63.4)
>100 49 (27.1) 12 (15.0) 37 (36.6)
Postoperative hospitalization (days, median, range) 5, 1–22 4.5, 1–22 6, 1–15 0.008*
Pathological type 0.13
Adenocarcinoma 155 (85.6) 65 (81.3) 90 (89.1)
Others 26 (14.4) 15 (18.7) 11 (10.9)
Tumor size (cm, median, range) 3.2, 0.7–9.0 3.75, 1.2–8.0 3.0, 0.7–9.0 0.004*
Malignant pleural nodule <0.001*
Localized 43 (23.8) 9 (11.2) 34 (33.7)
Diffused 138 (76.2) 71 (88.8) 67 (66.3)
Best T stage 0.112
T1 13 (7.2) 3 (3.7) 10 (9.9)
T2 80 (44.2) 27 (33.7) 53 (52.5)
T3 33 (18.2) 17 (21.3) 16 (15.8)
T4 39 (21.6) 18 (22.5) 21 (20.8)
Tx 16 (8.8) 15 (18.8) 1 (1.0)
Best N stage <0.001*
N0 50 (27.6) 8 (10.0) 42 (41.6)
N1 26 (14.4) 13 (16.3) 13 (12.9)
N2 66 (36.5) 29 (36.3) 37 (36.6)
N3 8 (4.4) 7 (8.7) 1 (1.0)
Nx 31 (17.1) 23 (28.7) 8 (7.9)
VATS, video-assisted thoracoscopic surgery. *The bold values represented the statistically significant values.
A similar result was observed for PFS (sublobar resection vs.
lobectomy, 20.0 vs. 15.0 months; P = 0.425) (Figures 1C,D).
Notably, Patients underwent lobectomy had a significantly larger
tumor size (P < 0.001) and less diffused MPN (48% vs. 84.1%,
P < 0.001), and more patients with lobectomy underwent
thoracotomy (76% vs. 25%, P < 0.001) and lymph node
resection (96% vs. 18.2%, P < 0.001) than patients with sublobar
resection. Patients with resection of the primary tumor, either
sublobar resection or lobectomy, had better survival than patients
undergoing biopsy alone (P < 0.001 and P= 0.003, respectively).
Additionally, in the resection group, no statistical difference
was observed regarding the OS of patients with systemic
lymphadenectomy, lymph node sampling and no lymph node
resection (P = 0.380).
With regard to the surgical approaches, patients underwent
VATS showed significantly better prognosis than patients
underwent thoracotomy (median OS, 47.0 vs. 37.0 months; P =
0.043). Subgroup analysis demonstrated a similar result in the
resection group (median OS, 68.0 vs. 40.0 months; P = 0.006;
median PFS, 20.0 vs. 16.0 months; P = 0.029) (Figures 1E–H),
while no survival difference was observed in the biopsy group
(median OS, 33.0 vs. 27.0 months; P = 0.484).
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FIGURE 1 | The survival analyses of the clinicopathological characteristics in non-small cell lung cancer (NSCLC) patients with unexpected pleural dissemination (PD).
(A,B) Comparison of postoperative overall survival (OS) and progression-free survival (PFS) of NSCLC patients with unexpected PD in primary tumor resection group
and biopsy alone group. (C,D) Comparison of OS and PFS of NSCLC patients with unexpected PD in sublobar resection group and lobectomy group. (E,F)
Comparison of OS and PFS of NSCLC patients with unexpected PD in video-assisted thoracic surgery (VATS) group and thoracotomy group. (G,H) Subgroup
analysis of OS and PFS of NSCLC patients with unexpected PD in resection group with or without VATS. (I,J) Comparison of OS and PFS of NSCLC patients with
(Continued)
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FIGURE 1 | unexpected PD receiving targeted therapy or not. (K) Comparison of OS of NSCLC patients with unexpected PD having anaplastic lymphoma kinase
(ALK) rearrangement, epidermal growth factor receptor (EGFR) mutation, or not. (L) Comparison of OS of NSCLC patients with unexpected PD having different
subtypes of EGFR mutation.
No significant survival benefit was observed concerning the
amount of MPN in patients within groups (localized vs. diffused,
median OS, 46.0 vs. 39.0 months; P = 1.0) or subgroups (biopsy
group, P = 0.667; resection group, P = 0.082).
Patients who received targeted therapies had significantly
better survival than those not (median OS, 51.0 vs. 25.0 months;
P < 0.0001) (Figures 1I,J), as well as patients with positive
EGFR mutations (median OS, 53.0 vs. 34.0 months; P = 0.005).
Subgroup analysis also showed a better survival for patients
with targeted therapies (median OS, biopsy group, 49.0 vs. 19.0
months, P < 0.001; resection group, 55.0 vs. 47.0 months, P =
0.034). Additionally, the patients with ALK rearrangement had
no survival difference with patients with EGFR mutation [mean
OS, 48.1 (95%CI: 41.7–54.5) vs. 55.7 (95%CI: 48.1–63.2)months;
P = 0.367], but they both had significantly longer survival than
patients without mutation [mean OS, 36.2 (95% CI: 29.2–43.3)
months; P= 0.011 or P= 0.001, respectively] (Figure 1K). As for
the subtypes of EGFR mutation, patients with a deletion in exon
19 had significantly better survival than patients with a point
mutation in exon 21 [mean OS, 69.7 (95% CI: 59.2–80.1) vs. 47.4
(95% CI: 38.5–56.3) months; P = 0.024] (Figure 1L).
Risk Factors for Prognosis
Univariate (Table 3) and multivariate (Figure 2) analyses
indicated that primary tumor resection [hazard ratio (HR) 0.52,
95% CI 0.31–0.87, P = 0.012], adjuvant targeted therapy (HR
0.40, 95% CI 0.25–0.65, P < 0.001), and tumor size ≤3 cm
(HR 0.44, 95% CI 0.25–0.76, P = 0.004) were associated with
increased OS, while primary tumor resection (HR 0.52, 95% CI
0.34–0.80, P = 0.003) and tumor size ≤3 cm (HR 0.57, 95% CI
0.37–0.86, P = 0.008) were associated with increased PFS among
patients with unexpected PD. Additionally, subgroup analysis
in resection group demonstrated that resection type was not
associated with better survival by Cox regression model (HR
1.323, 95% CI 0.743–2.357, P = 0.342).
DISCUSSION
According to the criteria of 7th and 8th lung cancer TNM staging
(4, 5), NSCLC with PD is classified as stage IV (M1a), due to
which patients with PD are not recommended for the surgical
invention. However, in the clinic, surgeons are sometimes
faced with the unexpected PD detected during surgery, which
is unidentifiable in preoperative examinations, or suspected
pleural nodules, which could not be verified due to the lack
of histological evidence. Under these circumstances, surgeons
have to decide to stop surgery or go on. Recently, emerging
evidence have shown that primary tumor resection could provide
survival benefits for NSCLC with malignant PD (1, 7–12, 21,
22), which promoted the re-evaluation of the surgical roles in
this type of disease, particularly with the rapid development
of VATS with less postoperative pain, shorter hospital stays,
and fewer complications (23). However, some of the studies
have the limitation of small sample size, patient selection bias
(containing patients with pleural effusion, contralateral nodules,
or no pathological confirmation of PD), or lack of control group
(1, 7, 12, 14–19). Taken together, more studies are needed to
investigate the value of surgical treatment for patients with
unexpected intraoperative PD (13).
According to the previous studies, the OS, 3- and 5-year
survival rate of NSCLC patients with PD were 15–52 months,
25.2–69.2% and 16.0–42.7%, respectively (1, 7–9, 11, 17, 21, 22,
24). Furthermore, the OS, 3- and 5-year survival rate were 20–64
months, 45.8–82.9%, and 31.4–42.7% for patients with primary
tumor resection, while 7–35 months, 11.8–41.7%, and 0–19.5%
for patients with biopsy alone. Our results were similar to these
favorable clinical outcomes. Even the outcomes of the biopsy
group in this study were better than the previous clinical data
(5-year survival rate, 2%; median OS, 9.5–11.5 months), which
supports the opinion that unexpected intraoperative PD may
belong to a relatively earlier stage than clinical diagnosed PD
(5, 6, 10, 25).
PD represents a wide range of disease states from a single
metastasis nodule to diffused pleural nodules involving in
pericardium and diaphragm with a large amount of pleural
effusion. The tumor burden of these states is different. On the
one hand, with the application of high-resolution CT and PET,
most PD cases could be diagnosed before surgery. So those
unexpected intraoperative PD cases were in the relatively early
stage of M1a. Ren et al. pointed out the same thesis as well
(7). On the other hand, according to the NCCN guidelines
for oligometastatic NSCLC (M1b), surgical resection of primary
lesion and metastasis can be beneficial for these patients (6).
Theoretically, the tumor burden of PD (M1a) is less than M1b,
hence the surgery may also be of advantage to the unexpected PD
patient’s survival. In this study, the results did show a survival
benefit for unexpected PD patients from surgery with a median
OS of 41 months. Consistent with our outcomes, a Japanese
study of 313 NSCLC patients with PD demonstrated that patients
underwent macroscopic complete resection had better survival
than patients with exploratory thoracotomy (11). Also, Shen et al.
(10) reported a retrospective study of patients with stage M1a
NSCLC, in which the patients who underwent primary tumor
resection had a significantly better OS than patients accepted no
surgery or only metastatic tumor resection (P < 0.001).
Another possible reason for the favorable results is related
to adjuvant therapies, especially targeted therapy. In our
study, the majority of patients (166 of 168, 98.8%) underwent
postoperative adjuvant therapies. The significantly better survival
was observed in patients who received postoperative targeted
therapy than those who did not, which suggests that NSCLC
patients with unexpected PD can benefit from mutation
tests and targeted therapies (11). In the context of the
rapid development of anti-tumor drugs, it may be possible
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TABLE 3 | Univariate analysis of prognostic factors.


































































CI, confidential interval; VATS, video-assisted thoracoscopic surgery. *The bold values represented the statistically significant values.
to be more active in surgical treatment when encountering
unexpected PD.
As for the types of surgical resections, no statistical difference
in survival between sublobar resection and lobectomy was
observed, similar results were found in some previous studies
(7, 8, 10, 12, 17, 24). Notably, the heterogeneity between
subgroups of lobectomy and sublobar resection may influence
the conclusion, making it difficult to determine which was the
best type of resection. Okamoto and Ohta both found that
patients received pneumonectomy had a significantly worse
survival than patients with limited resection (1, 15). However,
a study conducted by Iida et al. showed an opposite view that
the survival for patients with macroscopic complete resection
was statistically better than patients withmacroscopic incomplete
resection (P = 0.009) and exploratory thoracotomy (P < 0.001)
(11). Moreover, no statistical difference in survival was observed
between patients who underwent systemic lymphadenectomy
and not (P = 0.29) in our study. The study by Ren et al.
also indicated that neither systemic lymphadenectomy nor
pleurectomy made difference in survival significantly (7). In
summary, more evidences are required to clarify the optimum
resection type in these patients, although surgical intervention
seemsmore like a cytoreductive surgery in the PD cases. Sublobar
resection by video-assisted thoracoscopic surgery may be a
proper choice for the less invasiveness.
Our data demonstrated that patients underwent VATS had
a significant better survival, compared with those underwent
thoracotomy. However, the multivariate analysis did not support
this result. Therefore, the survival difference may be caused by
potential bias. Although with the advances of minimally invasive
surgery, including robotic-assisted thoracoscopic surgery, better
surgical outcomes may improve the patients’ quality of life.
Additionally, the extent of pleural diffusion is a complex variable,
which is difficult to analyze due to the ambiguous definition
and limited sample size, and may have a potential influence on
the prognosis. Li et al. defined diffused pleural nodules as more
than three pleural nodules, and their results showed diffused
MPN had no survival difference with localized MPN (11, 12). In
our study, there was no significant survival difference between
localized MPN and diffused MPN among all patients or in the
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FIGURE 2 | Prognostic factors of non-small cell lung cancer patients with unexpected pleural dissemination after surgery. (A) The forest plot of multivariate Cox
regression analysis for overall survival. (B) The forest plot of multivariate Cox regression analysis for progression-free survival. VATS, video-assisted thoracic surgery.
*statistically significant.
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resection group, although the biopsy group had more patients
with diffused MPN. This indicated that patients with less MPN
tended to be selected for resection. It needs more research to
clarify the prognosis influence of the MPN.
In this study, univariate and multivariate analyses
demonstrated that primary tumor resection, targeted adjuvant
therapy, and tumor size ≤3 cm were independent predictors
of survival in NSCLC patients with unexpected PD. These
may suggest that surgeons select unexpected PD patients
with small tumor size for resection and perform sensitive
mutation detection for targeted therapy, routinely. The
previous studies have reported similar prognosis factors to
ours (7, 12, 21, 26). However, the time span of this study was
relatively short and recent (6 years from 2010) compared with
other studies (1, 16, 17, 19, 24), and no patient was lack of
pathological confirmation for malignant PD, unlike other studies
(16, 19). Besides, the sample size of this study was relatively
larger than previous studies, as well as longer follow-up time
(1, 7, 12, 14, 15, 22). Additionally, several studies reported that
N0 stage was the independent prognostic factor for survival,
which, however, has potential bias, given that many patients did
not have completely pathological N status (1, 26). Therefore, the
N stage was not included in our model.
The major limitation of our study was its retrospective nature.
Additionally, there were some potential differences between the
two groups, such as the number of pleural nodules and the
pathological N stage, leading to the selection bias because there
is no consensus on how to choose patients with unexpected
PD who can benefit surgical resections. Third, limited resection
and no systemic lymphadenectomy could not provide enough
information for final pathological staging. Large sample multi-
center studies should be conducted in the future to verify the
efficacy of surgical procedures in NSCLC patients with PD.
CONCLUSION
NSCLC patients with unexpected PD diagnosed intraoperatively
potentially benefited from surgical resection of the primary
tumor and multidisciplinary therapies. Patients with targeted
adjuvant therapy and primary tumor size ≤3 cm had a better
prognosis. Our data demonstrated that the resection type was
not associated with survival differences, which, however, may
be influenced by the heterogeneity of the resection group.
Further studies on whether the type of surgical resections
(sublobar resection vs. lobectomy) affects the survival remain to
be determined.
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